M&A Deal Summary

Debiopharm Group Acquires Affinium Pharmaceuticals

On February 11, 2014, Debiopharm Group acquired life science company Affinium Pharmaceuticals

Acquisition Highlights
  • This is Debiopharm Group’s 1st transaction in the Life Science sector.
  • This is Debiopharm Group’s 1st transaction in Canada.
  • This is Debiopharm Group’s 1st transaction in Ontario.

M&A Deal Summary
Date 2014-02-11
Target Affinium Pharmaceuticals
Sector Life Science
Buyer(s) Debiopharm Group
Deal Type Add-on Acquisition

Target

Affinium Pharmaceuticals

Toronto, Ontario, Canada
Affinium Pharmaceuticals, Ltd. operates as clinical and preclinical antibacterial compounds and its technology platform.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Debiopharm Group

Lausanne, Switzerland
Category Company
Founded 1979
Sector Healthcare Services
DESCRIPTION

Debiopharm is a global biopharmaceutical group of four companies specializing in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2014) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-19 Kaiku Health

Helsinki, Finland

Kaiku Health Ltd. is a digital health company that monitors patient-reported outcomes, providing intelligent symptom tracking and management for healthcare providers in routine oncology care and studies. The Kaiku Health app screens for patients’ symptoms, notifies the care team on their development, and provides value-based personalized support for patients. Kaiku Health was formed in 2012 and is based in Helsinki, Finland.

Sell -
Mergr

Product

Company

Legal